Korro Bio Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company develops genetic medicines that utilize RNA editing to treat rare and highly prevalent diseases. Its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform recruits endogenous enzymes like ADAR to enable precise, transient single-base edits on RNA transcripts, repairing disease-causing mutations or modulating protein function without altering DNA. This oligonucleotide-based approach leverages established delivery methods such as GalNAc conjugation for liver targeting. Korro Bio Inc.'s lead program, KRRO-110, targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder causing lung and liver damage, and is in Phase 1/2 clinical trials. The company is also advancing KRRO-121 for hyperammonemia associated with urea cycle disorders and hepatic encephalopathy, along with programs in cardiometabolic diseases through a collaboration with Novo Nordisk, and explorations in Parkinson's disease and amyotrophic lateral sclerosis. Korro Bio Inc. focuses on liver-targeted and other tissue-specific therapies, positioning RNA editing as a tunable alternative in genetic medicine.